Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Cell Biochem ; 82(2): 339-55, 2001.
Article in English | MEDLINE | ID: mdl-11527158

ABSTRACT

The small and large intestines differ in their expression profiles of Bcl-2 homologs. Intestinal segment-specific Bcl-2 homolog expression profiles are acquired as early as by mid-gestation (18-20 weeks) in man. In the present study, we examined the question whether such distinctions underlie segment-specific control mechanisms of intestinal cell survival. Using mid-gestation human jejunum and colon organotypic cultures, we analyzed the impact of growth factors (namely insulin; 10 microg/ml) and pharmacological compounds that inhibit signal transduction molecules/pathways (namely tyrosine kinases, Fak, P13-K/Akt, and MEK/Erk) on cell survival and Bcl-2 homolog expression (anti-apoptotic: Bcl-2, Bcl-X(L), Mcl-1; pro-apoptotic: Bax, Bak, Bad). The relative activation levels of p125Fak, p42Erk-2, and p57Akt were analyzed as well. Herein, we report that (1) the inhibition of signal transduction molecules/pathways revealed striking differences in their impact on cell survival in the jejunum and colon (e.g., the inhibition of p125Fak induced apoptosis with a significantly greater extent in the jejunum [approximately 43%] than in the colon [approximately 24%]); (2) sharp distinctions between the two segments were noted in the modulatory effects of the various treatments on Bcl-2 homolog steady-state levels (e.g., inhibition of tyrosine kinase activities in the jejunum down-regulated all anti-apoptotics analyzed while increasing Bax, whereas the same treatment in the colon down-regulated Bcl-X(L) only and increased all pro-apoptotics); and (3) in addition to their differential impact on cell survival and Bcl-2 homolog expression, the MEK/Erk and P13-K/Akt pathways were found to be distinctively regulated in the jejunum and colon mucosae (e.g., insulin in the jejunum increased p42Erk-2 activation without affecting that of p57Akt, whereas the same treatment in the colon decreased p42Erk-2 activation while increasing that of p57Akt). Altogether, these data show that intestinal cell survival is characterized by segment-specific susceptibilities to apoptosis, which are in turn linked with segmental distinctions in the involvement of signaling pathways and the regulation of Bcl-2 homolog steady-state levels. Therefore, these indicate that cell survival is subject to segment-specific control mechanisms along the proximal-distal axis of the intestine.


Subject(s)
Apoptosis/physiology , Colon/cytology , Gene Expression Regulation, Developmental , Intestinal Mucosa/cytology , Jejunum/cytology , MAP Kinase Kinase Kinase 1 , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins c-bcl-2/physiology , Proto-Oncogene Proteins/metabolism , Signal Transduction/physiology , Apoptosis/drug effects , Apoptosis/genetics , Carrier Proteins/metabolism , Cell Survival , Colon/embryology , Colon/metabolism , Enzyme Activation/drug effects , Fetal Proteins/metabolism , Focal Adhesion Kinase 1 , Focal Adhesion Protein-Tyrosine Kinases , Genes, bcl-2 , Gestational Age , Humans , Insulin/pharmacology , Intestinal Mucosa/drug effects , Intestinal Mucosa/embryology , Intestinal Mucosa/metabolism , Jejunum/embryology , Jejunum/metabolism , MAP Kinase Signaling System , Membrane Proteins/metabolism , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3 , Mitogen-Activated Protein Kinases/metabolism , Myeloid Cell Leukemia Sequence 1 Protein , Neoplasm Proteins/metabolism , Organ Culture Techniques , Organ Specificity , Phosphatidylinositol 3-Kinases/metabolism , Protein Serine-Threonine Kinases/metabolism , Protein-Tyrosine Kinases/antagonists & inhibitors , Proto-Oncogene Proteins c-akt , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Proto-Oncogene Proteins c-bcl-2/metabolism , bcl-2 Homologous Antagonist-Killer Protein , bcl-2-Associated X Protein , bcl-Associated Death Protein , bcl-X Protein
2.
J Biol Chem ; 276(24): 21885-94, 2001 Jun 15.
Article in English | MEDLINE | ID: mdl-11283019

ABSTRACT

The intracellular signaling pathways responsible for cell cycle arrest and differentiation along the crypt-villus axis of the human small intestine remain largely unknown. p38 mitogen-activated protein kinases (MAPKs) have recently emerged as key modulators of various vertebrate cell differentiation processes. In order to elucidate further the mechanism(s) responsible for the loss of proliferative potential once committed intestinal cells begin to differentiate, the role and regulation of p38 MAPK with regard to differentiation were analyzed in both intact epithelium as well as in well established intestinal cell models recapitulating the crypt-villus axis in vitro. Results show that phosphorylated and active forms of p38 were detected primarily in the nuclei of differentiated villus cells. Inhibition of p38 MAPK signaling by 2-20 microm SB203580 did not affect E2F-dependent transcriptional activity in subconfluent Caco-2/15 or HIEC cells. p38 MAPK activity dramatically increased as soon as Caco-2/15 cells reached confluence, whereas addition of SB203580 during differentiation of Caco-2/15 cells strongly attenuated sucrase-isomaltase gene and protein expression as well as protein expression of villin and alkaline phosphatase. The binding of CDX2 to the sucrase-isomaltase promoter and its transcriptional activity were significantly reduced by SB203580. Pull-down glutathione S-transferase and immunoprecipitation experiments demonstrated a direct interaction of CDX3 with p38. Finally, p38-dependent phosphorylation of CDX3 was observed in differentiating Caco-2/15 cells. Taken together, our results indicate that p38 MAPK may be involved in the regulation of CDX2/3 function and intestinal cell differentiation.


Subject(s)
Cell Differentiation/physiology , Homeodomain Proteins/metabolism , Intestinal Mucosa/cytology , Intestinal Mucosa/metabolism , Mitogen-Activated Protein Kinases/metabolism , Transcription Factors/metabolism , CDX2 Transcription Factor , Cell Cycle/physiology , Cell Division , Cell Line , Cell Survival , Enzyme Activation , Enzyme Inhibitors/pharmacology , Fetus , Gestational Age , Humans , Imidazoles/pharmacology , Intestinal Mucosa/embryology , MAP Kinase Signaling System/physiology , Pyridines/pharmacology , Recombinant Proteins/metabolism , Trans-Activators , Transfection , p38 Mitogen-Activated Protein Kinases
3.
Am J Physiol ; 245(2): G249-56, 1983 Aug.
Article in English | MEDLINE | ID: mdl-6881348

ABSTRACT

Bombesin (BBS) was infused in conscious fasting dogs to document its effects on the release of motilin in the blood and on intestinal motility. When BBS was infused for 3 h (0.125 and 0.5 microgram X kg-1 X h-1), a specific pattern of myoelectric activity was induced: 1) the pacesetter potentials were increased in frequency but decreased in amplitude; 2) a moderate spike activity (weak phase II) was superimposed on this disorganized pacesetter activity, and activity fronts were abolished despite elevated motilin levels. A second experiment was performed in which motilin levels during BBS administration for a selected period of an interdigestive myoelectric complex (IDMC) could be compared with those obtained at a similar period of a preceding IDMC in which a saline solution had been infused. The motilin blood levels measured during BBS administration (0.25, 0.5, 1.0, and 2.0 micrograms X kg-1 X h-1 for 20 min each stepwise) were significantly higher than those obtained with saline. The administration of BBS synchronized with the IDMC was necessary to document its effect on motilin release, because when BBS was infused at an unknown period of the IDMC no rise of motilin levels over basal could be detected. Because of its contradictory effects on the release of motilin (stimulation of motilin release) and on the IDMC (inhibition of motilin effect), a physiological role of BBS as an endocrine regulator of motilin release is questionable. On the other hand, the possibility that BBS controls motilin release in a paracrine or neurocrine role cannot be excluded.


Subject(s)
Bombesin/pharmacology , Gastrointestinal Hormones/metabolism , Motilin/metabolism , Myenteric Plexus/physiology , Peptides/pharmacology , Action Potentials/drug effects , Animals , Dogs , Duodenum/innervation , Electric Conductivity , Kinetics , Motilin/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...